Inhibrx, Inc. (NASDAQ:INBX) Accelerates Toward Near-Term Re-Rating After Clinical Updates
Recent clinical disclosures and investor-material updates have concentrated catalysts into the coming months, leaving technical momentum and balance-sheet strength to shape near-term repricing.








